PharmaShots | Incisive News in 3 Shots

Subscribe Now

fresenius kabi

Fresenius Kabi and Formycon Report the US FDA’s Approval of Otulfi (Biosimilar, Stelara)

Fresenius Kabi and Formycon Report the US FDA’s Approval of Otulfi (Biosimilar, Stelara)

October 1, 2024

Fresenius Reports the US FDA’s BLA Acceptance of FKS518 (Biosimilar, Denosumab)

Fresenius Reports the US FDA’s BLA Acceptance of FKS518 (Biosimilar, Denosumab)

May 28, 2024

Fresenius Kabi Launches Tyenne (Biosimilar, Actemra; IV) to Treat Chronic Autoimmune diseases

Fresenius Kabi Launches Tyenne (Biosimilar, Actemra; IV) to Treat Chronic Autoimmune diseases

April 15, 2024

Fresenius Kabi Reports the US FDA’s Approval for Tyenne (Biosimilar, tocilizumab-aazg) as a Treatment of Immunological and Oncological Indications

Fresenius Kabi Reports the US FDA’s Approval for Tyenne (Biosimilar, tocilizumab-aazg) as a Treatment of Immunological and Oncolog...

March 7, 2024

Fresenius Kabi Launches Tyenne, Europe’s First Tocilizumab Biosimilar for Inflammatory Diseases and COVID-19

Fresenius Kabi Launches Tyenne, Europe’s First Tocilizumab Biosimilar for Inflammatory Diseases and COVID-19

November 1, 2023

Fresenius Kabi’s Tyenne (biosimilar, tocilizumab) Receives EC’s Approval for Multiple Inflammatory and Immune Mediated Conditions

Fresenius Kabi’s Tyenne (biosimilar, tocilizumab) Receives EC’s Approval for Multiple Inflammatory and Immune Mediated Conditions

September 20, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us